Tiziana Life Sciences Reports Six-Month Qualitative Results For All 10 Non-Active Secondary Progressive Multiple Sclerosis Patients Enrolled In Intermediate-Size Patient Population Expanded Access Program
Tiziana Life Sciences Reports Six-Month Qualitative Results For All 10 Non-Active Secondary Progressive Multiple Sclerosis Patients Enrolled In Intermediate-Size Patient Population Expanded Access Program
tiziana life sciences向所有10名非活性次进展性多发性硬化患者报告了为期六个月的定性结果，这些患者参加了中等规模患者群体扩展接触计划。
- Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.
- FDA Allowance for an additional 20 Patients to be enrolled in the intranasal foralumab Multiple Sclerosis Expanded Access Program will allow further data collection and analysis.
- Applied for FDA Orphan Drug Designation of foralumab for na-SPMS
- 80%接受鼻内foralumab治疗至少6个月的非活动性继发性多发性硬化（na-SPMS）扩展使用患者 PET 成像显示定性改善。
- FDA允许额外招募20名患者参加鼻内foralumab多发性硬化扩展使用计划，以便进一步收集和分析数据。
- 申请FDA孤儿药物foralumab治疗na-SPMS的认定。